LY
Lyell Immunopharma, Inc.
LYEL · NASDAQ
$11.01 +4.31% (+$0.46)
1M -25.31%
Market Cap $269.8M
P/E Ratio -
Div. Yield -
ROE 91.62%
Piotroski F-Score Weak
1/9Valuation
50 /100
Fair P/S 9,992.33x
P/B 1.15x
P/E N/A
Growth
0 /100
Declining Rev. growth 92.48%
Book val. growth 33.22%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 8,537.04%
Net margin 920,285.00%
FCF margin 496,189.00%
Quality
0 /100
Poor ROIC 70.80%
ROE 91.62%
Asset turnover 0.00x
Debt
100 /100
Low Debt/Equity 0.16x
Current ratio 5.36x
Int. coverage N/A
Stability
21 /100
Unstable Beta -0.07x
Rev. volatility 31.09%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre LYEL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Lynn Seely
Employees
161
Headquarters
South San Francisco
Evenimente viitoare
10 NOV.
Earnings
Upcoming earnings report